OM
Omnicell, Inc.
OMCL · NASDAQ
$32.23 -0.62% (-$0.20)
1M -9.42%
Market Cap $1.48B
P/E Ratio 37.96x
Div. Yield -
ROE 3.13%
Bulios Fair Price
$28
13.1% downside
Current Price
$32.23
Undervalued Fair Value Overvalued
According to Bulios Fair Price, OMCL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
68 /100
Cheap EV/EBITDA 13.12x
P/S 1.19x
P/B 1.15x
Growth
31 /100
Declining Rev. growth 2.94%
FCF growth 72.11%
Book val. growth 2.91%
Profitability
51 /100
Moderate Net margin 3.13%
Op. margin 4.73%
FCF margin 11.34%
Quality
18 /100
Poor ROE 3.13%
ROA 1.96%
Asset turnover 0.62x
Debt
97 /100
Low Current ratio 1.64x
Int. coverage 15.94x
Net debt/EBITDA -0.87x
Stability
57 /100
Moderate Rev. volatility 9.01%
EPS volatility 320.35%
Profitable years 2
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about OMCL
Online
Sector
Healthcare
Industry
Medical - Healthcare Information Services
CEO
Randall A. Lipps
Employees
3,485
Headquarters
Fort Worth
Upcoming events
29 OCT
Earnings
Upcoming earnings report